Fine-tuning pharmacogenetics: Paradigm for linking laboratory results to clinical action

Clinical Chemistry

Volumn 50, Issue 9, 2004, Pages 1498-1499

  Valdes Jr , Roland ^a   Linder, Mark W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EDUCATION; CLINICAL LABORATORY; CLINICAL PRACTICE; COMMUNITY MEDICINE; DOSE CALCULATION; EDITORIAL; GENE DOSAGE; GENOTYPE PHENOTYPE CORRELATION; PATIENT CARE; PHARMACOGENETICS; PREDICTION; PRESCRIPTION;

AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHEMISTRY, CLINICAL; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE;

EID: 4344691022     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.037515     Document Type: Editorial

References (8)

1. Linder MW, Prough RA, Valdes R Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997;43:254-66.
2. Valdes R Jr., Linder MW, Jortani SA. What is next in pharmacogenomics? Translating it to clinical practice. Pharmacogenomics 2003;4:499-505.
3. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, et al. Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
4. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-95.
5. Raimundo S, Fischer J. Eichelbaum M, Griese EU, Schwab M, Zanger UM. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000;10:577-81.
6. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22.
7. Steimer W, Zopf K, von Amelunxen S, Pfeiffer H, Bachofer J, Popp J, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004;50:1623-33.
8. National Academy of Clinical Biochemistry (NACB) web site. www.nacb.org.